Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAINBO NSMP-ORANGE: Adjuvant Treatment in Endometrial Cancer
NCT07831902Phase 3Recruiting
- Sponsor
- University College London
- Start
- Jun 2026
- Primary completion
- Dec 2030
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of medroxyprogesterone acetate and megestrol in endometrial cancer (EC) (2 arms), sponsored by University College London. Primary endpoint: Recurrence free survival at 3 years. Started Jun 2026; status: recruiting.
02
Drugs
medroxyprogesterone acetatemegestrol
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT07831902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07831902.